News for Healthier Living
FDA Approval Opens New Chapter in Pancreatic Cancer Treatment
FDA Approval of Rasonque (daraxonrasib), represents a monumental shift in the treatment of pancreas cancer and demonstrates that RAS, one of the most important drivers of pancreatic cancer, can be successfully targeted.
August 27, 2026
August 30 2026August 29 2026August 28 2026August 27 2026August 26 2026August 25 2026August 24 2026August 21 2026August 20 2026August 19 2026August 18 2026August 17 2026August 16 2026
|
|
|
|
|